2026.02. 10 本文字数：2754，阅读时长大约4分钟 作者 | 第一财经 黄思瑜 2月10日，随着新股电科蓝天（688818.SH）上市，科创板上市公司总数达到603家，总市值达到 11.44万亿元。 截至目前，科创板逾390家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板块公司 总数的超六成；另有1家公司披露了科创板2025年度首份年报。从细分行业表现看，集成电路、生 物医药行业景气度回升。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。截至2月10日，科创综指样本数量 达580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发布时提升 15.1%。 东吴证券首席经济学家、研究所联席所长芦哲对第一财经称，预期未来3～5年，科创板总市值有望 翻倍，科创综指将同步成长为"万亿级产品规模、千亿级日成交"的核心宽基指数，不仅与沪深 300、创业板指并驾齐驱，更可能率先完成"本土指数—跨境ETF—全球定价"的三级跳，成为中国科 技创新实力对外展示的"首张名片"。 391家公司"交卷"，六成预增 目前，科创板上市公司数量合计603家，包括61家未盈利企业、9家 ...

2月10日，科创板又迎来新兵电科蓝天。目前，科创板上市公司总数达到603家。 作为中国"硬科技"企业的聚集地，科创板的板块产业图谱与现代化产业体系建设同向而行，尤其在新一 代信息技术、生物医药、高端装备制造等战略性新兴产业，已形成"链主引领、上下协同"的发展格局。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。推出一年来，科创综指的市场关注度 持续提升，截至2026年2月10日，科创综指样本数量达580只，市值覆盖度超过90%，总市值高于100亿 元的科创综指成份股权重占比较发布时提升15.1%，成长效应显著。 科创综指已成为与上证指数、深证成指、创业板指并列的A股四大核心宽基指数，为境内外投资者观测 和分享中国新质生产力发展红利提供了重要工具。 科创板近六成公司预告净利润同比增长 科创综指是定位于覆盖科创板全市场的综合指数，板块市值覆盖度超过90%。可以说，科创综指是分享 科创板公司成长发展成果的有力指标。 截至2026年2月9日，科创板共有391家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板 块公司总数的六成以上；另有1家公司芯导科技披露了科创板2025年度首份年报，以营收同比 ...

上证报中国证券网讯（记者 严曦梦）2月10日，以"赋新质启新程"为主题的2026张江科创金融沙龙在上海张江科学城举行。张通社联合加冕研究院第八年发 布《2025年张江企业融资榜单》（以下简称《榜单》）。 《榜单》基于公开融资事件数据，从融资规模、资本投向、融资阶段、企业质量与创新特征，以 及投资机构参与情况等多个维度，全面呈现张江科创金融生态的最新图景。 全年融资237起约占上海四分之一 根据《榜单》，2025年张江共有210家科创企 业完成融资，全年发生237起融资事件，披露融资金额278亿元；融资事件数同比增长30%，披露融资金额同比增长18%。 观察张江的全年表现，融资节奏呈 现出高度的均衡性与连续性，未出现阶段性的"冲量"或断档。平均每月约20起融资事件，反映出张江持续有项目在推进、有投资在落地。 从区域贡献看， 2025年张江融资规模约占浦东新区的65%，约占上海市的25%。这意味着，上海每4起科创融资中，就有1起发生在张江。 三大先导产业融资占比超九成 生 物医药最活跃 《榜单》显示，2025年，张江科创融资的行业投向更趋集中，发生在生物医药、人工智能、集成电路等上海三大先导产业的融资件数合计占 ...

"未来3～5年科创综指相关产品规模和体量仍有巨大发展空间。" 2月10日，随着新股电科蓝天（688818.SH）上市，科创板上市公司总数达到603家，总市值达到11.44万 亿元。 截至目前，科创板逾390家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板块公司总数 的超六成；另有1家公司披露了科创板2025年度首份年报。从细分行业表现看，集成电路、生物医药行 业景气度回升。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。截至2月10日，科创综指样本数量达 580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发布时提升15.1%。 东吴证券首席经济学家、研究所联席所长芦哲对第一财经称，预期未来3～5年，科创板总市值有望翻 倍，科创综指将同步成长为"万亿级产品规模、千亿级日成交"的核心宽基指数，不仅与沪深300、创业 板指并驾齐驱，更可能率先完成"本土指数—跨境ETF—全球定价"的三级跳，成为中国科技创新实力对 外展示的"首张名片"。 391家公司"交卷"，六成预增 目前，科创板上市公司数量合计603家，包括61家未盈利企业、9家特殊股权架构企业、7家红筹企业、 ...

Group 1: Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.58% to 27,183.15 points, the Hang Seng China Enterprises Index up by 0.81% to 9,242.75 points, and the Hang Seng Tech Index rising by 0.62% to 5,451.03 points [2] - Major technology stocks mostly saw gains, with JD.com, Xiaomi, and Alibaba each rising over 1% [3] Group 2: AI Application Stocks - AI application stocks experienced a significant surge, with Zhiyun rising over 21% at one point and closing up over 14%. Other notable gains included Reading Group up over 15% and Fubo Group up over 13% [5] - The attention on AI stocks was driven by the launch of a mysterious model named Pony Alpha on the OpenRouter platform, which quickly became popular among global developers due to its strong coding capabilities and deep optimization for intelligent workflows [5] Group 3: Biotechnology Sector - The biotechnology sector also performed well, with notable increases in stocks such as Fuhong Hanlin up over 7%, and WuXi Biologics and Rongchang Biologics each rising over 4% [6] - Guojin Securities anticipates a performance disclosure window for innovative drug companies in February and March, with expectations for many to reduce losses or turn profitable by 2026, supported by upcoming academic conferences [6]

中新网上海2月10日电张江硬核吸金力凸显，成为上海乃至中国科创资本的核心集聚高地。 在10日举行的2026张江科创金融沙龙上，《2025年张江企业融资榜单》对外发布。该榜单显示，2025 年，张江210家企业完成237起融资，披露金额达278亿元。 数据显示，张江企业的融资规模占浦东新区全区65%、上海全市25%，成为区域科创融资的核心引擎。 超512家投资机构参与张江投融资，国有资本、产业资本、市场化创投机构多元布局，资本结构持续优 化。 资本高度聚焦硬核科技赛道，生物医药、人工智能、集成电路三大先导产业融资合计占比91%，较2024 年提升9个百分点，其中生物医药以85起融资居首。融资阶段呈现早中后期协同集聚特征，早期融资占 比64%，彰显资本对张江初创科创企业的信心。 融资企业的科创硬实力成为吸金关键，其中8家实现全球首个技术突破、9家填补国内产业空白，还涵盖 75家高新技术企业、27家专精特新"小巨人"及33家独角兽企业，科创动能持续释放。 亮眼的融资成绩，源于张江构建的覆盖企业全生命周期的创新服务生态。上海市张江科学城建设管理办 公室主任、中国(上海)自由贸易试验区管理委员会张江管理局局长肖健表示， ...

截至2026年2月9日，科创板中共有391家公司以业绩预告或快报形式披露了2025年度业绩预测。已披露业绩预测的科创板公司中，近六成公司净利润实现 同比增长，其中39家净利润大幅增长100%以上、51家扭亏为盈。科创成长层企业中，寒武纪、奥比中光、精进电动、诺诚健华4家公司预计将在年报披露 后实现"摘U"。 从细分行业表现看，科创板集成电路、生物医药行业景气度回升。其中，集成电路产业受人工智能等新兴应用需求拉动，延续较高景气度，87家已披露业 绩预测的公司，合计净利润同比增加约99.49亿元，57家公司业绩预增或扭亏为盈。创新药行业受益于BD交易频出、出海提速，商业化进程显著加快，26 家公司合计净利润增加14.49亿元，18家披露营业收入的公司合计实现营业收入241.57亿元，同比增长34.9%。 科创综指也是分享改革红利的重要牵引。科创板自设立以来先后推进试点注册制、"科创板八条"、"科创板1+6"三轮系统性改革，着力提高资本市场制度 包容性、适应性。截至2月10日，科创板累计支持61家未盈利企业、9家特殊股权架构企业、7家红筹企业、23家第五套标准企业上市。未盈利上市企业中 22家上市后成功盈利"摘U" ...

Core Insights - The article highlights the transformation of Hunan's private economy, emphasizing the importance of technology, specialization, and integration for sustainable growth [1][26][49] Group 1: Technology as the Foundation - Hunan's private enterprises are increasingly focusing on technology and innovation as core competencies, moving beyond traditional manufacturing practices [3][29] - By 2025, private enterprises are expected to account for over 90% of all businesses in Hunan, contributing approximately 60% to the province's GDP [29] - Companies like Huazhu High-Tech are investing heavily in R&D, focusing on system-level development of equipment, materials, software, and processes rather than simple assembly [31][39] Group 2: Specialization and Craftsmanship - The concept of "specialization" is evident in companies like Warner Pharmaceutical, which emphasizes deep expertise and meticulous process improvements in drug development [37][46] - Warner Pharmaceutical's founder, Huang Bendong, advocates for a long-term commitment to research and development, reflecting a "craftsman spirit" in the pharmaceutical industry [37][46] - Water Sheep Co. has shifted from a marketing-driven approach to a research-driven model, focusing on product efficacy and quality through extensive R&D investments [33][41] Group 3: Integration for Growth - Water Sheep Co. exemplifies the integration of supply chain, data, and R&D capabilities, breaking down traditional barriers between branding, manufacturing, and consumer feedback [44][49] - Warner Pharmaceutical is adopting a cautious approach to integration, focusing on enhancing quality control and collaboration with research institutions while avoiding unrelated diversifications [46][48] - Huazhu High-Tech is not merely a technology supplier but aims to solve specific industry problems, fostering deeper collaborations with downstream clients [48][49]

Core Viewpoint - Tianjin's Development and Reform Commission has released a list of 1,112 key projects with a total investment of 1.82 trillion yuan, aiming to support high-quality development and achieve a strong start for the 14th Five-Year Plan [1][13]. Group 1: Investment and Project Overview - This year, Tianjin has arranged a total investment of 1.4 trillion yuan for 824 key construction projects, with an annual planned investment of 202.19 billion yuan and 288 key reserve projects totaling 422.47 billion yuan [1][13]. - During the 14th Five-Year Plan period, cumulative investment in key projects reached 1.19 trillion yuan, significantly supporting the city's stable economic growth [2][14]. Group 2: Focus Areas for Development - Key projects this year focus on the deep integration of technological innovation and industrial innovation, fostering new growth drivers, and implementing an innovation-driven development strategy [3][15]. - The emphasis is on intelligent and green integration in manufacturing, strengthening new industrial clusters in sectors such as aerospace, biomedicine, circular economy, and new energy materials [3][15]. - Modern service industry development is prioritized to enhance consumption potential and improve the quality and diversity of services [3][15]. Group 3: Major Engineering Initiatives - Eight major engineering initiatives have been proposed, including promoting coordinated development in the Beijing-Tianjin-Hebei region, advancing high-level technological self-reliance, and enhancing modern service industry capabilities [5][17]. - The focus is on strategic projects that have significant investment scales and strong driving effects, with 300 projects selected for key promotion [5][17]. Group 4: Infrastructure and Urban Development - Infrastructure projects include the acceleration of subway line constructions and improvements in urban drainage and heating systems to enhance urban resilience [8][21]. - Urban renewal projects are underway to optimize urban functionality and improve the quality of life for residents [8][21]. Group 5: Social Welfare and Rural Development - Initiatives are being implemented to improve rural living conditions, develop modern agriculture, and enhance social security systems to increase public satisfaction and well-being [4][16]. - The focus is on creating demonstration bases for rural revitalization and promoting high-value rural industries [9][22]. Group 6: Project Lifecycle and Support - The city will enhance services for key enterprises and projects, ensuring timely commencement and acceleration of construction [11][25]. - Comprehensive support will be provided for planning, land use, and funding to facilitate project development and investment quality improvement [11][25].

Group 1 - The core point of the article is that Chengdu XianDao (688222) plans to invest 24 million yuan in Chengdu XianYan Biological Technology Co., Ltd. at a pre-investment valuation of 450 million yuan [2] - Chengdu XianYan is a subsidiary and related party of Chengdu XianDao, with a registered capital of 17.2408 million yuan, and aims to raise no more than 150 million yuan for its development [2] - The company has established an innovative technology system including novel small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology, focusing on chronic disease treatment [2] Group 2 - The investment will increase Chengdu XianDao's stake in Chengdu XianYan, which currently holds 23.2% of the equity, with the final ownership percentage to be determined based on the total financing amount and the new registered capital [2]